Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
29.86 USD | +0.71% | +9.30% | -11.50% |
May. 08 | Needham Adjusts Price Target on Pacira BioSciences to $43 From $45, Keeps Buy Rating | MT |
May. 07 | Transcript : Pacira BioSciences, Inc., Q1 2024 Earnings Call, May 07, 2024 |
Strengths
- The company's profit outlook over the next few years is a strong asset.
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The company is in a robust financial situation considering its net cash and margin position.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Weaknesses
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-11.50% | 1.38B | B- | ||
+32.36% | 698B | C+ | ||
+26.51% | 568B | B | ||
-4.40% | 358B | C+ | ||
+19.46% | 328B | B- | ||
+3.50% | 283B | C+ | ||
+16.34% | 238B | B+ | ||
+6.68% | 203B | B- | ||
-9.08% | 198B | A+ | ||
+8.62% | 165B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- PCRX Stock
- Ratings Pacira BioSciences, Inc.